Selecta Biosciences, Inc.
Selecta Biosciences, Inc. (SELB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
selb · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Selecta Biosciences, Inc. (SELB) measures how much investors pay for each dollar of the company's trailing earnings. SELB's current PE ratio of N/A is calculated by dividing its stock price of $0.88 by its TTM earnings per share of -$5.65.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Selecta Biosciences, Inc.You SELB | $135M | N/A | — | -$5.65 |
 aTyr Pharma, Inc. ATYR | $43M | N/A | — | -$0.80 |
 Cyteir Therapeutics, Inc. CYT | $109M | N/A | — | -$1.25 |
 Decibel Therapeutics, Inc. DBTX | $123M | N/A | — | -$2.52 |
 F-star Therapeutics, Inc. FSTX | $157M | N/A | — | -$1.88 |
 Kinnate Biopharma Inc. KNTE | $125M | N/A | — | -$2.42 |
 NGM Biopharmaceuticals, Inc. NGM | $129M | N/A | — | -$1.73 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-5.02 | — | |
2024-12-31 FY2024 | — | $-0.50 | — | |
2023-12-31 FY2023 | — | $-1.42 | — | |
2022-12-31 FY2022 | 4.62x | $0.24 | — | |
2021-12-31 FY2021 | — | $-0.22 | — | |
2020-12-31 FY2020 | — | $-0.69 | — | |
2019-12-31 FY2019 | — | $-1.18 | — | |
2018-12-31 FY2018 | — | $-2.92 | — | |
2017-12-31 FY2017 | — | $-3.20 | — | |
2016-12-31 FY2016 | — | $-1.97 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Selecta Biosciences, Inc. (SELB) measures how much investors pay for each dollar of the company's trailing earnings. SELB's current PE ratio of N/A is calculated by dividing its stock price of $0.88 by its TTM earnings per share of -$5.65.
Frequently asked questions
SELB pe ratio · 6 questionsSELB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.88 and TTM EPS of -$5.65. Data sourced from Financial Modeling Prep via SELB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Selecta Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09